Diabetes
Guideline | Remission of type 2 diabetes
27 Jan, 2023 | 12:18h | UTCUser’s Guide: Remission of Type 2 Diabetes – Canadian Journal of Diabetes
Cohort Study | Dietary exposure to nitrites and nitrates linked to increased risk of type 2 diabetes
26 Jan, 2023 | 12:54h | UTCCommentaries:
What is the association between nitrite and nitrate exposure and type 2 diabetes? – News Medical
Total Nitrite Consumption Tied to Higher Type 2 Diabetes Risk – HealthDay
SR | Does reducing your salt intake help to prevent and treat chronic kidney disease in people with diabetes?
25 Jan, 2023 | 11:30h | UTC
Review | Cardiovascular outcomes in type 1 and type 2 diabetes
23 Jan, 2023 | 13:18h | UTCCardiovascular outcomes in type 1 and type 2 diabetes – Diabetologia
Commentary on Twitter
Useful review of Cardiovascular outcomes in type 1 and type 2 diabeteshttps://t.co/mDECkFbZCq pic.twitter.com/q7J74FkNgJ
— Prof Kamlesh Khunti (@kamleshkhunti) January 20, 2023
Article under a http://creativecommons.org/licenses/by/4.0/. License
M-A of Observational Studies | Physical activity and risk of major diabetes-related complications in individuals with diabetes
23 Jan, 2023 | 13:17h | UTC
Commentary on Twitter
Dose-response meta-analysis on physical activity and diabetes-related complications in prospective studies. Even at low levels, physical activity was associated with lower relative risk of complications. @DiabResearch
Read Here➡️https://t.co/x0ElyfWEDH pic.twitter.com/tcLRIsLExP
— Diabetes Care, a research journal of the ADA (@DiabetesCareADA) December 7, 2022
Consensus Statement | Proposed algorithm for pharmacotherapy in people with type 2 diabetes
20 Jan, 2023 | 14:41h | UTCRelated: Guideline | ADA 2023 Standards of Medical Care in Diabetes.
Consensus Recommendations | Sick day medication guidance for people with diabetes, kidney, or cardiovascular disease
19 Jan, 2023 | 14:31h | UTC
Commentary on Twitter
Consensus Recommendations for Sick Day Medication Guidance for People With Diabetes, Kidney, or Cardiovascular Diseasehttps://t.co/wqgzRNwAWt @disasterpharmy @VerdinNancy @kelsea_drall @MaoliosaDonald @Ross_Tsuyuki @nipannu @UCalgaryMed @UAlberta_DoM #VisualAbstract pic.twitter.com/j8ZMzLSmxQ
— AJKD (@AJKDonline) December 7, 2022
2022 Consensus Guidelines on the management of diabetes in children
19 Jan, 2023 | 14:16h | UTCEditorial: ISPAD Clinical Practice Consensus Guidelines 2022
ISPAD Clinical Practice Consensus Guidelines 2022: Diabetes technologies: Glucose monitoring
ISPAD Clinical Practice Consensus Guidelines 2022: Managing diabetes in preschoolers
Crossover RCT | Preliminary study showed closed-loop insulin delivery might improve glycemic control in some adults with Type 2 DM
15 Jan, 2023 | 19:56h | UTCNews Release: Artificial pancreas successfully trialed for use by type 2 diabetes patients – University of Cambridge
Commentary: Artificial Pancreas Device May Help Folks With Type 2 Diabetes – HealthDay
M-A | The prevalence of obesity among children with type 2 DM
12 Jan, 2023 | 12:53h | UTCCommentary: Not All Pediatric Cases of Type 2 Diabetes Have Obesity – HealthDay
Commentary on Twitter
Meta-analysis finds that 75% of children with type 2 diabetes have obesity; not all pediatric T2DM patients have obesity. Further studies are needed to investigate the mechanisms beyond obesity driving this condition in children. https://t.co/RsDVSDq7rq
— JAMA Network Open (@JAMANetworkOpen) December 16, 2022
Guideline Synopsis | Diabetes management in chronic kidney disease
10 Jan, 2023 | 14:52h | UTCCommentary: Layered Approach Recommended for Patients With Diabetes, CKD – HealthDay
Original Guideline: KDIGO 2022 Clinical practice guideline for diabetes management in chronic kidney disease.
RCT | Effect of an intermittent calorie-restricted diet on Type 2 DM remission.
16 Dec, 2022 | 13:43h | UTCEffect of an Intermittent Calorie-restricted Diet on Type 2 Diabetes Remission: A Randomized Controlled Trial – The Journal of Clinical Endocrinology & Metabolism (link to abstract – $ for full-text)
Commentaries:
Expert reaction to study looking at intermittent fasting and type 2 diabetes – Science Media Centre
Intermittent Fasting Can Achieve Remission in Type 2 Diabetes – HealthDay
Commentary on Twitter
Can an intermittent fasting (IF) diet reverse Type 2 diabetes?
A small randomized trial says yes, w/ 47% of IF-assigned participants achieving remission for at least 1 year vs 3% of controls (odds ratio of 31; yes, too good to be true)https://t.co/Ths3LrNL8u
Worth further study pic.twitter.com/VwOqMeAAJr— Eric Topol (@EricTopol) December 14, 2022
Guideline | ADA 2023 Standards of Medical Care in Diabetes.
14 Dec, 2022 | 15:59h | UTCGuideline Homepage: ADA 2023 Standards of Medical Care in Diabetes – American Diabetes Association
Introduction: Standards of Medical Care in Diabetes—2023
Summary of Revisions: Standards of Medical Care in Diabetes—2023
- Improving Care and Promoting Health in Populations: Standards of Care in Diabetes—2023
- Classification and Diagnosis of Diabetes: Standards of Care in Diabetes—2023
- Prevention or Delay of Type 2 Diabetes and Associated Comorbidities: Standards of Care in Diabetes—2023
- Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes—2023
- Facilitating Positive Health Behaviors and Well-being to Improve Health Outcomes: Standards of Care in Diabetes—2023
- Glycemic Targets: Standards of Care in Diabetes—2023
- Diabetes Technology: Standards of Care in Diabetes—2023
- Obesity and Weight Management for the Prevention and Treatment of Type 2 Diabetes: Standards of Care in Diabetes—2023
- Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2023
- Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023
- Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2023
- Retinopathy, Neuropathy, and Foot Care: Standards of Care in Diabetes—2023
- Older Adults: Standards of Care in Diabetes—2023
- Children and Adolescents: Standards of Care in Diabetes—2023
- Management of Diabetes in Pregnancy: Standards of Care in Diabetes—2023
- Diabetes Care in the Hospital: Standards of Care in Diabetes—2023
- Diabetes Advocacy: Standards of Care in Diabetes—2023
Consensus Statement | Continuous glucose monitoring and metrics for clinical trials.
15 Dec, 2022 | 13:42h | UTCContinuous glucose monitoring and metrics for clinical trials: an international consensus statement – The Lancet Diabetes & Endocrinology (free registration required)
Commentary on Twitter
Online—Continuous glucose monitoring and metrics for clinical trials: an international consensus statement https://t.co/hrNXB9ycr0 #CGM #diabetes #FREE to read with registration (also FREE) #IDF2022 pic.twitter.com/x40lzAL1by
— The Lancet Diabetes & Endocrinology (@TheLancetEndo) December 7, 2022
RCT | A calorie-unrestricted low-carbohydrate, high-fat diet resulted in short-term weight loss and better glycemic control.
14 Dec, 2022 | 15:08h | UTCEffect of Calorie-Unrestricted Low-Carbohydrate, High-Fat Diet Versus High-Carbohydrate, Low-Fat Diet on Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial – Annals of Internal Medicine (link to abstract – $ for full-text)
Commentary: Low-Carbohydrate, High-Fat Diet Beneficial in T2DM in Short Term – HealthDay
Summary for Patients: Effect of Calorie-Unrestricted Low-Carbohydrate, High-Fat Diet Versus High-Carbohydrate, Low-Fat Diet on Type 2 Diabetes and Nonalcoholic Fatty Liver Disease – Annals of Internal Medicine
Commentary on Twitter
RCT finds low-carb diet beats low-fat diet for weight loss and glucose control in patients with #type2diabetes over 6-month intervention, but changes not sustained. @AleksanderKrag @Camilla_Dalby @FLASH_OUH: https://t.co/4v58k8KK4x pic.twitter.com/zwgIBDCxCB
— Annals of Int Med (@AnnalsofIM) December 13, 2022
Review | GLP-1 receptor agonists for the reduction of atherosclerotic cardiovascular risk in patients with Type 2 Diabetes.
13 Dec, 2022 | 14:29h | UTCGLP-1 Receptor Agonists for the Reduction of Atherosclerotic Cardiovascular Risk in Patients With Type 2 Diabetes – Circulation (free for a limited period)
Global burden of type 2 diabetes in adolescents and young adults, 1990-2019.
9 Dec, 2022 | 13:37h | UTCNews Release: Substantial rise in type 2 diabetes among young people – British Medical Journal
Guideline | Management of individuals with diabetes at high risk for hypoglycemia.
8 Dec, 2022 | 13:08h | UTC
Guideline | Psychological care of children, adolescents and young adults with diabetes.
6 Dec, 2022 | 13:53h | UTC
Practical Guidance | Insulin pumps and hybrid close loop systems within hospital.
5 Dec, 2022 | 00:16h | UTC
Case–control study | GLP-1 receptor agonists linked to increased risk of thyroid cancer.
25 Nov, 2022 | 12:42h | UTCGLP-1 Receptor Agonists and the Risk of Thyroid Cancer – Diabetes Care (link to abstract – $ for full-text)
Commentary: GLP-1 receptor agonists associated with thyroid cancer – ACP Internist
RCT | Intermittently scanned continuous glucose monitoring vs. fingerstick testing for Type 1 DM.
21 Nov, 2022 | 14:45h | UTCRCT | Intermittently scanned continuous glucose monitoring vs. fingerstick testing for Type 1 DM.
Intermittently Scanned Continuous Glucose Monitoring for Type 1 Diabetes – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary: Continuous Monitoring Outperforms Fingerstick Testing in Patients With T1D, High Glycated Hemoglobin – AJMC
Commentary on Twitter
In persons with type 1 diabetes, intermittently scanned continuous glucose monitoring led to significantly lower glycated hemoglobin levels than participant monitoring with fingerstick testing. https://t.co/2JkNKDyoQJ pic.twitter.com/CXEcARsLD8
— NEJM (@NEJM) October 5, 2022
Guideline | Management of hyperosmolar hyperglycemic state in adults.
15 Nov, 2022 | 13:03h | UTC
M-A | SGLT2 inhibitors reduce the risk of kidney disease progression and AKI, irrespective of diabetes status.
11 Nov, 2022 | 14:04h | UTCCommentaries:
Meta-analysis backs SGLT2 inhibitors for kidney disease – medwire News
EMPA-KIDNEY: Empagliflozin a ‘Win’ for Patients With CKD – TCTMD
Commentary on Twitter
Our SGLT2 Trialists Consortium meta-analysis *the largest ever* in @TheLancet https://t.co/YlWkRQTDAW
Definitive evidence that SGLT2i ⬇️:
– Kidney failure
– AKI
– CV death
– All-cause deathRegardless of diabetes
Led by @NatalieStaplin @RichardHaynes3 @willkidney #AHA22 pic.twitter.com/uAX15mD9XY
— Brendon Neuen (@brendonneuen) November 6, 2022
Under a Creative Commons Attribution (CC BY 4.0) License
M-A | Head-to-head trials comparing sulfonylureas and low hypoglycemic risk antidiabetic drugs.
11 Nov, 2022 | 13:38h | UTC